Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Security and risk in the 21st century

What are the major security risks in the 21st century and how should we deal with them? Pranav Ganta is part of the 25th anniversary cohort and will be studying […]

The benefits of bilingualism

Professor Napoleon Katsos is from the first cohort of Gates Cambridge Scholars. Minhee Lee is from the 2025 cohort. Napoleon will be Minhee’s supervisor as she explores the multi-layered meanings […]

‘Personality test’ shows how AI chatbots mimic human traits – and how they can be manipulated

Researchers, including first co-author by Gregory Serapio-García [2019], have developed the first scientifically validated ‘personality test’ framework for popular AI chatbots, and have shown that chatbots not only mimic human […]

Can we use AI to colour outside the lines?

Eryk Salvaggio [2025] and Tristan Dot [2022] are both interested in the questions thrown up by AI art, but they come at it from different perspectives.  Before Cambridge, Tristan studied […]